Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy
Open Access
- 4 October 2022
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 27, 230-245
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Leukemia and Lymphoma Society of Canada (622735)
- Leukemia and Lymphoma Society of Canada (430053)
- Santé
- Cole Foundation
This publication has 48 references indexed in Scilit:
- PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cellsJournal of Clinical Investigation, 2013
- Transferred WT1-Reactive CD8 + T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant PatientsScience Translational Medicine, 2013
- Paths to stemness: building the ultimate antitumour T cellNature Reviews Cancer, 2012
- Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral InfectionsMolecular Therapy, 2012
- Antigen-Independent Induction of Tim-3 Expression on Human T Cells by the Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Is Associated with Proliferation and Is Dependent on the Phosphoinositide 3-Kinase PathwayThe Journal of Immunology, 2012
- Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling PathwaysMolecular and Cellular Biology, 2011
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemiaBlood, 2011
- siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen–specific CD8+ T cellsBlood, 2010
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityJournal of Experimental Medicine, 2010
- Adoptive cell transfer: a clinical path to effective cancer immunotherapyNature Reviews Cancer, 2008